Principal Financial Group Inc. Buys 26,441 Shares of Omnicell, Inc. $OMCL

Principal Financial Group Inc. grew its stake in Omnicell, Inc. (NASDAQ:OMCL) by 9.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 296,321 shares of the company’s stock after buying an additional 26,441 shares during the period. Principal Financial Group Inc.’s holdings in Omnicell were worth $9,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in OMCL. Raymond James Financial Inc. acquired a new position in shares of Omnicell during the second quarter valued at about $26,000. Clearstead Advisors LLC increased its stake in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after acquiring an additional 1,218 shares during the period. Kemnay Advisory Services Inc. bought a new position in Omnicell during the fourth quarter valued at about $58,000. Parkside Financial Bank & Trust raised its holdings in Omnicell by 1,708.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after acquiring an additional 1,264 shares in the last quarter. Finally, First Horizon Corp raised its holdings in Omnicell by 54.6% in the 4th quarter. First Horizon Corp now owns 1,597 shares of the company’s stock valued at $72,000 after acquiring an additional 564 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 10th. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Wells Fargo & Company upped their target price on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday, April 23rd. Craig Hallum reiterated a “buy” rating and set a $55.00 price target on shares of Omnicell in a research note on Wednesday, April 29th. Finally, Zacks Research downgraded shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $59.86.

Omnicell Stock Performance

NASDAQ:OMCL opened at $41.00 on Friday. The firm has a market capitalization of $1.86 billion, a PE ratio of 93.18, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12-month low of $27.77 and a 12-month high of $55.00. The firm has a 50-day moving average price of $42.40 and a 200 day moving average price of $41.40.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million for the quarter, compared to the consensus estimate of $304.02 million. During the same period in the previous year, the business earned $0.26 earnings per share. The company’s quarterly revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Research analysts anticipate that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Insider Activity at Omnicell

In other Omnicell news, EVP Corey J. Manley sold 5,025 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $217,180.50. Following the sale, the executive vice president directly owned 112,783 shares in the company, valued at $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total value of $133,549.80. Following the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by company insiders.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.